Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

LEXINGTON, Mass., Nov. 25 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced its consolidated results of operations for the fiscal year and the three-month period ended September 30, 2008. The Company will host a conference call and webcast today beginning at 9:00 am eastern time (details follow below).

The Company reported fiscal 2008 consolidated revenues of $77.8 million, an increase of 18% from fiscal 2007 revenues of $66.1 million. For the three- month period ended September 30, 2008, the Company reported consolidated revenues of $23.3 million, a decrease of 21% from the $29.5 million reported for the three-month period ended September 30, 2007. The three-month period ended September 30, 2007 included a one-time, up-front recognition of $13.0 million related to the approval milestone for SANCTURA XR(TM) from Allergan.

For fiscal 2008, the Company reported a consolidated net loss of $65.6 million, or $0.86 per share, compared to a consolidated net loss of $103.8 million or $1.61 per share for fiscal 2007. Fiscal 2008 results include one- time restructuring charges of approximately $3.0 million. For the three-month period ended September 30, 2008, the Company reported a consolidated net loss of $14.0 million or $0.18 per share, compared to a consolidated net loss of $8.8 million or $0.12 per share for the three-month period ended September 30, 2007.

At September 30, 2008, the Company had consolidated cash, cash equivalents and marketable securities totaling approximately $131.3 million.

"Fiscal 2008 was extremely active for the Company," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The year ended on a very strong note and the Company is in excellent shape to have a successful coming year. In particular, we now have a
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/22/2014)... Chicago, Illinois (PRWEB) December 22, 2014 ... representing tenants and occupiers of commercial real estate, has ... two new offices in Perth and Brisbane, Western Australia, ... board of directors. , ITRA Global / ACORPP ... and totally independent consultancy company providing property services to ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... July 8 Cornerstone Therapeutics Inc. (Nasdaq: ... special meeting of its stockholders on August 27, 2009. ... will be asked to approve a series of amendments ... implement governance arrangements and provide Chiesi Farmaceutici SpA with ...
... SAN DIEGO, July 8 Biomatrica today announced that ... SampleMatrix room temperature storage technology to archive its DNA ... SampleMatrix technology in place of ultra-low-temperature freezers for the ... SMGF will move its collection of previously archived samples ...
... Researchers at Cellular Dynamics ... pluripotent stem cells, which have the ability to generate all ... ordinary human blood samples. This significant breakthrough provides a readily ... samples in storage at blood repositories and healthcare institutions worldwide. ...
Cached Biology Technology:Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 2Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 3Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 4Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 5Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica's Room Temperature Storage 2Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica's Room Temperature Storage 3Cellular Dynamics International Reprograms Blood Cells into Stem Cells 2
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... has been shown to cause pain by exciting the ... and the hot, spicy ingredient in chili peppers, UCSF ... plants and animals have evolved the same molecular strategy ... specific receptor on sensory nerves. The research provides new ...
... hold promise for reducing the destruction of dopaminergic cells ... lost to the disease, scientists say. , Research ... Neuroscience shows a human neural stem cell transplant essentially ... normally rather than displaying the progressive loss of movement ...
... discovered that mutations in a gene known as SOS1 ... common childhood genetic disorder which occurs in one in ... stature, facial abnormalities, and learning disabilities, as well as ... Led by researchers at Harvard Medical School-Partners Healthcare ...
Cached Biology News:Tarantula venom and chili peppers target same pain sensor 2Transplanted brain cells hold promise for Parkinson's disease 2Transplanted brain cells hold promise for Parkinson's disease 3Study uncovers mutation responsible for Noonan Syndrome 2
Gentamicin sulfate, 5g...
E2F2 protein...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Biology Products: